HK Stock MarketDetailed Quotes

09688 ZAI LAB

Watchlist
  • 21.650
  • -0.200-0.92%
Not Open Dec 11 16:08 CST
23.52BMarket Cap-11.18P/E (TTM)

About ZAI LAB Company

Zaiding Pharmaceutical is an innovative biopharmaceutical company based in China and operating globally. It is committed to providing patients in China and around the world with innovative drugs in the fields of cancer, autoimmunity and infectious diseases. Zaiding Pharmaceutical is headquartered in Shanghai. Since its establishment in 2014, it has established partnerships with many of the world's leading biopharmaceutical companies to create a broad product line of late-stage innovative drug candidates. For global biopharmaceutical companies seeking to enter the Chinese market and find long-term strategic partners for international clinical development, Zaiding Pharmaceutical has become one of the most trustworthy partner candidates in the industry with a series of successful cooperation cases. Through these successful collaborations, Zaiding Pharmaceutical has built the strongest advanced cancer product pipeline among innovative Chinese biotech companies, with several first-in-class and/or best-in-class drugs in the world. At the same time, we are continuously improving our internal R&D capabilities to further supplement our product line. The goal is to have 1-2 global new drug clinical trial applications (INDs) each year in the future. Zaiding Pharmaceuticals is rapidly developing into a fully integrated biopharmaceutical company that discovers, develops, produces and commercializes innovative drugs in China and around the world. To this end, we have set up an internal R&D center in China to promote drug research and development, built a strong clinical development and operation team, and established our own production base. In addition, we have set up a specialized commercial team to support the promotion of innovative products in China. We believe this integrated strategy will bring a sustainable competitive advantage to Zaiding Pharmaceuticals. Zaiding Pharmaceutical was successfully listed on the US NASDAQ in September 2017. Since then, the company has developed rapidly. It has set up branches or offices in many parts of China, and established the US headquarters in San Francisco in December 2018. As of December 2019, the company had approximately 700 employees worldwide.

Company Profile

Symbol09688
Company NameZAI LAB
ISINKYG9887T1168
Listing DateSep 28, 2020
Issue Price562.00
Shares Offered10.56M share(s)
FoundedMar 28, 2013
Registered AddressCayman Islands
Chairmanying du
Secretarylini ouyang
Audit InstitutionKPMG LLP, KPMG
Company CategoryOverseas registration of Mainland Individuals control
Registered OfficeHarbour Place 2nd Floor 103 South Church Street P.O. Box 472 George Town Grand Cayman KY1-1106 Cayman Islands
Head Office and Principal Place of BusinessRoom 2301, 23rd floor, Hong Kong Transport Building, 510 King's Road, North Point, Hong Kong
Fiscal Year Ends12-31
Employees2010
MarketHong Kong motherboard
Phone(852)38448100
Fax(86)2161632570
Emailmedia@zailaboratory.com
Business Zai Lab Ltd is a biopharmaceutical holding company focused on discovering, licensing, developing and commercializing proprietary therapies to address a large number of unmet medical needs in the Chinese market, including oncology, autoimmunity, and infectious diseases. The company has a range of patented drug candidates from the discovery phase to the later stages of clinical projects. These include Niraparib (ZL-2306), ZL-2103, and ZL-1101.

Company Executives

  • Name
  • Position
  • Salary
  • ying du
  • Chairman, CEOs, Directors, Authorized Representative
  • 13.79M
  • John D. Diekman
  • Independent Directors, Audit Committee Members, Nomination Committee Members, Remuneration Committee Members
  • --
  • kaixian chen
  • Independent Directors
  • 312.00K
  • Richard Gaynor
  • Independent Directors
  • 567.00K
  • yingyu liang
  • Independent Directors
  • --
  • William Lis
  • Independent Directors, Nomination Committee Members
  • 321.00K
  • Leon O. Moulder, Jr.
  • Independent Directors, Chairman of the Nomination Committee, Remuneration Committee Members
  • 328.00K
  • Scott W. Morrison
  • Independent Directors, Chairman of the Audit Committee
  • 573.00K
  • Michel Pericles Vounatsos
  • Independent Non-Executive Director
  • 278.00K
  • Peter Wirth
  • Independent Directors, Remuneration Committee Chairman, Audit Committee Members
  • 330.00K
  • Rafael G.Amado
  • President of Global Development in Oncology
  • --
  • yajing chen
  • Chief Financial Officer
  • --
  • F. Ty Edmondson
  • Joint Company Secretary, Chief Legal Officer
  • --
  • Harald Reinhart
  • President, Head of Global Development for the Central Nervous System, Autoimmunity, and Anti-Infectious Diseases
  • --
  • Joshua Smiley
  • President, Chief Operating Officer
  • --
  • lini ouyang
  • Joint Company Secretary, Authorized Representative
  • --
Heat List
HK
Overall
Symbol
Price
% Chg

No Data